Moyamoya Disease Market - A Puzzling Disease Insight into the Future from Market Research Future | 2018-2023

Market Highlight:

Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and seizures.

According to the National Organization for Rare Diseases, in Japan, moyamoya disease is estimated to occur in 1 per 1 million people, and the condition is more prevalent in females under the age of 20. It is also reported that nearly 10% of cases of moyamoya disease in Asian countries have a genetic cause. Recently, two major mutations have been found to be associated with a specific population of moyamoya patients i.e. R179, and RNF213 mutations.

Request a Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/5275

Moyamoya Disease Market Key Companies Analyzed In Report Are

Abbott Laboratories, Boston Scientific Corporation, Cephalon, Inc., Cordis Corporation, Eisai Co., Ltd, GE Healthcare, Genentech Inc., GlaxoSmithKline PLC., Johnson & Johnson, Koninklijke Philips N.V., Medtronic plc, Merck & Co. Inc., Novartis AG, Pfizer, Inc., Sanofi, Siemens, Stryker,, Sunovion Pharmaceuticals, Inc., UCB Pharma Ltd., Valeant Pharmaceuticals International, Inc. and others.

Market Segmentation:

The global moyamoya disease market is segmented on the basis of diagnosis, treatment, and distribution channels.

On the basis of the diagnosis, the market is classified as a cerebral angiogram, magnetic resonance imaging (MRI), magnetic resonance angiogram (MRA), computed tomography (CT) scans, transcranial Doppler ultrasound, positron emission tomography (PET) scan, and electroencephalography (EEG).

On the basis of the treatment, the market is classified as surgical treatment and non-surgical treatment. The surgical treatment is further classified as pial synangiosis, indirect procedures, and direct arterial bypass. The sub-segment of indirect procedures includes EDAS (encephaloduroarteriosynangiosis), EMS (encephalomyosynangiosis), Omental transposition/transfer, and dural inversion. The non-surgical treatment is further classified as anticoagulation and antiplatelet therapy, and others. The sub-segment of anticoagulation and antiplatelet therapy include heparin, warfarin, aspirin, and others.

On the basis of the distribution channel, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.

Intended Audience

• Pharmaceutical Companies
• Research and Development (R&D) Companies
• Diagnostic Laboratories
• Government Research Institute
• Academic Institutes and Universities

Detailed Regional Analysis:

The Americas dominate the moyamoya disease market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.

Europe holds the second position in the moyamoya disease market. It is expected that the support provided by the government bodies for research & development and improvement in the reimbursement policies in the healthcare is likely to drive the market of Europe region.

The Asia Pacific is the fastest growing moyamoya disease market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.

The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.

Get Exclusive Discount on Report @ https://www.marketresearchfuture.com/check-discount/5275

Some Brief Table of Contents of Report

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations

Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation

Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment

TOC Continued…

Do You Have Specific Requirement? Ask To Our Experts@ https://www.marketresearchfuture.com/enquiry/5275

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future

Hadapsar, Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.